Zobrazeno 1 - 9
of 9
pro vyhledávání: '"phase 4 clinical trial (topic)"'
Patient-reported outcome measures (PROMs), tools to assess patient self-report of health status, are now increasingly used in research, care and policymaking. While there are two well-developed disease-specific PROMs for interstitial lung diseases (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______9436::c8d6a4b575973560a91e4b5a52e47255
https://hdl.handle.net/11454/79739
https://hdl.handle.net/11454/79739
Autor:
Stylianopoulos, T., Jain, R. K.
Publikováno v:
Nanomedicine: Nanotechnology, Biology, and Medicine
Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the fact that the enhanced perm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33012a731bbf62b14b0e58c7cdb4288
https://doi.org/10.1016/j.nano.2015.07.015
https://doi.org/10.1016/j.nano.2015.07.015
Autor:
Bernabe, Rosemarie D L C, Wangge, Grace, Knol, Mirjam J, Klungel, Olaf H, van Delden, Johannes J M, de Boer, Anthonius, Hoes, Arno W, Raaijmakers, Jan A M, van Thiel, Ghislaine J M W, Sub Pharmacotherapy, Theoretical, Dep Farmaceutische wetenschappen, Sub Gen. Pharmacoepi and Clinical Pharm, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
BMC Medical Research Methodology
BMC Medical Research Methodology [E], 13. BioMed Central
BMC Medical Research Methodology [E], 13. BioMed Central
BACKGROUND: Non-inferiority (NI) trials in drug research are used to demonstrate that a new treatment is not less effective than an active comparator. Since phase IV trials typically aim at informing a clinical decision, the value of a phase IV non-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655472ccbee5104b22fac231d310afed
https://dspace.library.uu.nl/handle/1874/310462
https://dspace.library.uu.nl/handle/1874/310462
Autor:
Boet, Sylvain1,2,3 (AUTHOR) sboet@toh.ca, Burns, Joseph K.1,2 (AUTHOR), Cheng-Boivin, Olivia4 (AUTHOR), Khan, Hira5 (AUTHOR), Derry, Kendra1 (AUTHOR), Diep, Deric1 (AUTHOR), Djokhdem, Abdul Hadi4 (AUTHOR), Um, Sung Wook6 (AUTHOR), Huang, Johnny W.4 (AUTHOR), Paré, Danica4 (AUTHOR), Deng, Mimi4 (AUTHOR), Begunova, Liza7 (AUTHOR), Fei, Linda Yi Ning4 (AUTHOR), Bezzahou, Maryam4 (AUTHOR), Andrahennadi, Pium Sonali4 (AUTHOR), Grose, Elysia4 (AUTHOR), Abebe, Ruth G8 (AUTHOR), Mansour, Fadi4 (AUTHOR), Talbot, Zoé4 (AUTHOR), Dion, Pierre-Marc9 (AUTHOR)
Publikováno v:
Systematic Reviews. 10/26/2021, Vol. 10 Issue 1, p1-9. 9p.
Autor:
Sun, A.1 ccopgi@mcmaster.ca, Durocher-Allen, L. D.2, Ellis, P. M.3,4, Ung, Y. C.5, Goffin, J. R.3, Ramchandar, K.6, Darling, G.7
Publikováno v:
Current Oncology. Jun2019, Vol. 26 Issue 3, pe372-e384. 13p.
Publikováno v:
Pain Physician; Dec2021, Vol. 24 Issue 8, p495-506, 18p
Autor:
Fluyau, Dimy, Revadigar, Neelambika
Publikováno v:
Frontiers in Psychiatry; 4/24/2017, Vol. 8, p1-8, 8p
Publikováno v:
Annals of Behavioral Medicine; Apr2016, Vol. 50 Issue 2, p210-236, 27p, 1 Diagram, 6 Charts, 1 Graph
Autor:
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda
Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis)